The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of May 31, 2017:
- 43 negotiations are currently underway with 9 new files added since the last update of April 30, 2017:
- Brivlera (brivarcetam): Used to treat partial-onset seizures
- Butrans (buprenorphine): Used to treat persistent pain of moderate intensity
- Ibrance (palbociclib): Used to treat advanced breast cancer
- Invega Trinza (paliperidone palmitate): Used to treat schizophrenia
- Invokamet (canaglifllozin/metformin hydrochloride): Used to treat type 2 diabetes mellitus
- Kuvan (sapropterin dihydrochloride): Used to treat Phenylketonuria (PKU)
- Mifegymiso (mifepristone/misoprostol): Used for the medical termination of pregnancy
- Quinsair (levofloxacin): Used to treat cystic fibrosis with chronic Pseudomonas aeruginosa infections
- Taltz (ixekizumab): Used to treat moderate to severe plaque psoriasis
- 153 joint negotiations have been completed with 4 files successfully negotiated since the last update of April 30, 2017:
- Cotellic (cobimetinib): Used to treat metastatic melanoma
- Humira (adalimumab): Used to treat ulcerative colitis
- Rituxan SC (rituximab): Used to treat multiple indications
- Vectibix (panitumumab): Used to treat metastatic colorectal cancer
- 50 drug products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level with no new files added since the last update of April 30, 2017.
- 13 negotiations for brand name drug products have been recommended by the pCPA to be considered by each Province/Territory individually with no new files added since the last update of April 30, 2017.
For more information, please consult the pCPA’s website.